Buy & Sell J M Smucker Co (SJM) – J M Smucker Co Price Today
Aura AI Summary
Key Stats
- $10.72BMarket Cap
- Consumer StaplesSector
- -22.82%3M Drawdown
- $18.12BEnterprise Value
- 4.38%Dividend Yield
- 78 daysTypical Hold Time
J M Smucker Co (SJM) is currently valued at a market capitalization of $10.72B, with an enterprise value of $18.12B. Over the past 52 weeks, J M Smucker Co has traded between a low of $89.53 and a high of $116, highlighting its annual price range. Over the past three months, J M Smucker Co has recorded a drawdown of -22.82%, reflecting recent price volatility. J M Smucker Co offers a dividend yield of 4.38%, with the most recent dividend of $1.10 paid on 15 May 26. On average, investors hold J M Smucker Co for approximately 78 days, indicating typical investor behavior on the platform.
About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Most Recent News
SpaceX IPO could boost Congresswoman McClain's stake profit by up to 86% of her annual salary.
SpaceX has filed for an IPO with a target valuation of $1.75 to $2 trillion, potentially making CEO Elon Musk a trillionaire. Congresswoman Lisa McClain owns a stake in SpaceX through a prior investment in xAI, which merged with SpaceX. Depending on ...
Zoom Video preps Q1 earnings with 4.2% revenue growth, AI expansion, but slight EPS dip expected
Zoom Video Communications will report Q1 earnings on May 21, 2026, with analysts expecting $1.41 EPS and $1.22 billion revenue, a 4.2% increase from last year. Growth is driven by AI expansion and strong Zoom Phone service adoption, despite a slight ...
30+ pharma firms accelerate clinical trials for new cutaneous T-cell lymphoma drugs
Over 30 pharmaceutical companies are actively developing more than 30 drugs for cutaneous T-cell lymphoma (CTCL), a rare skin-related non-Hodgkin lymphoma. Key players like Prescient Therapeutics and Innate Pharma are advancing promising therapies th...